Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
As seen on the 24/7 Wall St. homepage on November 2, 2026.
Quarterly net product sales passed $1 billion for the first time, powered by newly acquired VYKAT XR, INGREZZA and a CRENESSITY line that more than doubled. Management raised full-year INGREZZA guidance and trimmed SG&A, a direct answer to the slide in the shares heading into results.
Continue ReadingShow less
Neurocrine Biosciences cleared $1 billion in net product sales for the first time, with Q3 2026 revenue of $1.12 billion beating expectations.
INGREZZA carried the quarter at $801 million in net sales, with CRENESSITY and the newly acquired VYKAT XR adding the rest.
Sponsored
Management raised full-year INGREZZA guidance and trimmed SG&A guidance, pointing to improving operating leverage.
Phase 3 readouts for osavampator and direclidine land in 2027, with an R&D Day set for December 15, 2026. Cash fell to roughly $790 million after the Soleno acquisition.
Mentioned: NBIX